Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

CNS 14Gastrointestinal 7Head & Neck 3Genitourinary 3Sarcoma 2Tumor-Agnostic 1Other solid neoplasm 1Gynecologic 1Endocrine 1Breast 1

Conditions

Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Kidney Neoplasms 1

Interventions

Docetaxel 390pembrolizumab 325Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Ferrosoferric Oxide × Genitourinary × Clear all
NCT04369560 2025-12-17

Virtual Histology of the Bladder Wall for Bladder Cancer Staging

University of Pittsburgh

Phase EARLY_PHASE1 Recruiting
42 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT02141490 2019-09-06

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
43 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms, Kidney Neoplasms, Prostatic Neoplasms

NCT01296139 2018-07-05

Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
21 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡